- Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalAn arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for…BioPharma Dive · 20d ago↗ source
- Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnershipsSino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday. One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to AstraZ…Endpoints · 20d ago↗ source
- Satellos gives early look at Duchenne pill in adults ahead of key data in childrenSatellos Bioscience is building its case for a Duchenne muscular dystrophy pill with data in adult patients ahead of a potentially pivotal readout in children later this year. The Canadian biotech’…